ABSTRACT
PURPOSE: To gain knowledge of the repair tissue in critically sized cartilage defects using bone marrow stimulation combined with CARGEL Bioscaffold (CB) compared with bone marrow stimulation (BMS) alone in a validated animal model. METHODS: Six adult Göttingen minipigs received two chondral defects in each knee. The knees were randomized to either BMS combined with CB or BMS alone. The animals were euthanized after 6 months. Follow-up consisted of histomorphometry, immunohistochemistry, semiquantitative scoring of the repair tissue (ICRS II), and µCT of the trabecular bone beneath the defect. RESULTS: There was significantly more fibrocartilage (80% vs 64%, p = 0.04) and a trend towards less fibrous tissue (15% vs 30%, p = 0.05) in the defects treated with CB. Hyaline cartilage was only seen in one defect treated with CB and none treated with BMS alone. For histological semiquantitative score (ICRS II), defects treated with CB scored lower on subchondral bone (69 vs. 44, p = 0.04). No significant differences were seen on the other parameters of the ICRS II. Immunohistochemistry revealed a trend towards more positive staining for collagen type II in the CB group (p = 0.08). µCT demonstrated thicker trabeculae (p = 0.029) and a higher bone material density (p = 0.028) in defects treated with CB. CONCLUSION: Treatment of cartilage injuries with CARGEL Bioscaffold seems to lead to an improved repair tissue and a more pronounced subchondral bone response compared with bone marrow stimulation alone. However, the CARGEL Bioscaffold treatment did not lead to formation of hyaline cartilage.
ABSTRACT
The VISA-A questionnaire has proven to be a valid and reliable tool for assessing severity of Achilles tendinopathy (AT). The aim was to translate and cross-culturally adapt the VISA-A questionnaire for a Danish-speaking AT population, and subsequently perform validity and reliability tests. Translation and following cross-cultural adaptation was performed as translation, synthesis, reverse translation, expert review, and pretesting. The final Danish version (VISA-A-DK) was tested for reliability on healthy controls (n = 75) and patients (n = 36). Tests for internal consistency, validity, and structure were performed on 71 patients. VISA-A-DK showed good reliability for patients (r = 0.80 ICC = 0.79) and healthy individuals (r = 0.98 ICC = 0.97). Internal consistency was 0.73 (Cronbach's alpha). The mean VISA-A-DK score in AT patients was 51 [47-55]. This was significantly lower than healthy controls with a score of 93 (90-95). Criterion validity was considered good when comparing the scores of the Danish version with the original version in both healthy individuals and patients. VISA-A-DK is a valid and reliable instrument and has shown compatible to the original version in assessment of AT patients. VISA-A-DK is a useful tool in the assessment of AT, both in research and in a clinical setting.
Subject(s)
Achilles Tendon/physiopathology , Tendinopathy/physiopathology , Adult , Case-Control Studies , Cultural Competency , Cumulative Trauma Disorders/diagnosis , Cumulative Trauma Disorders/physiopathology , Denmark , Female , Humans , Male , Middle Aged , Reproducibility of Results , Severity of Illness Index , Surveys and Questionnaires , Tendinopathy/diagnosis , TranslationsABSTRACT
We have expressed horse cytochrome c in Escherichia coli. The gene was designed with E. coli codon bias and assembled by using a recursive polymerase chain reaction method. The far-ultraviolet and near-ultraviolet/Soret circular dichroism (CD) spectra show that the structure of recombinant horse cytochrome c is the same as that of the authentic protein. CD-detected thermal denaturation studies were used to measure the thermodynamic parameters associated with two-state denaturation. The free energy of denaturation for the recombinant protein is 10.0 +/- 2.3 kcal mol(-1) at pH 4.6 and 25 degrees C, which agrees with the value for the authentic protein. The expression system will help advance our understanding of the roles of cytochrome c in electron transfer, oxidative stress, and apoptosis by allowing the production of protein variants.
Subject(s)
Cytochrome c Group/chemistry , Cytochrome c Group/genetics , Escherichia coli/genetics , Amino Acid Sequence , Animals , Base Sequence , Circular Dichroism , Cytochrome c Group/biosynthesis , Cytochrome c Group/chemical synthesis , Escherichia coli/enzymology , Genes, Synthetic , Horses , Molecular Sequence Data , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemical synthesis , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , ThermodynamicsABSTRACT
Growth factors with specific effects on bone cells have been known of for more than a decade. Clinical usage of growth factors has recently become possible due to recombinant gene technology. In vivo studies over the last five years have demonstrated that growth factors can stimulate bone formation and bone healing and these results have made growth factors candidates for future clinical use in orthopaedic surgery. Growth factors for clinical use will become commercially available in the near future. The aim of this review paper is to describe the most important growth factors with effect on bone tissue and to give an updated review on experimental and clinical data on growth factor mediated bone healing in situations related to orthopaedic surgery. Possible areas for future clinical usage of growth factors are also discussed.
